Trial reportBMC research notes2025
Early use of neutral Protamine Hagedorn (NPH) insulin in the management of diabetic ketoacidosis: an open-label randomized controlled trial in a resource-limited setting.
Trial report in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveRegular insulin infusion and intravenous fluids are the cornerstones of managing diabetic ketoacidosis (DKA). To shorten the time taken to resolve DKA in known diabetic patients, the concomitant administration of glargine with regular insulin infusion has been tried, with promising results. This study primarily aimed to assess whether the addition of Neutral Protamine Hagedorn (NPH) insulin to continuous insulin infusion (CII) hastens the resolution of DKA. The secondary objectives were to compare the time to rebound hyperglycemia, frequency of hypoglycemia and duration of hospital stay between the early NPH insulin and control groups.
resultsAn open-label, randomised controlled trial (CTRI ref/2022/08/044760, dated August 8, 2022) of 50 adult participants with DKA was conducted from August 2022 to June 2023. In the intervention arm, 25 participants received 0.25 IU/kg subcutaneous NPH insulin in 2 divided doses, along with a continuous insulin infusion from the time of randomization until the primary outcome was achieved. The control arm (n = 25) received the standard of care. The time to resolution of DKA was significantly shorter in the intervention arm [Intervention (I): 20 (16-32) hours vs. Standard (S): 38.5 (27-48) hours] in those with severe DKA (p = 0.01). Rebound hyperglycemia was delayed in the intervention arm [I: 7.9 ± 2.7 h vs. S: 5.9 ± 2.2 h]. There was no significant difference in the duration of hospital stay or frequency of hypoglycemia. However, the small sample size restricts the generalizability of the results and, larger studies are needed for confirmation of these findings.
trial registrationThis trial was prospectively registered in the Clinical Trials Registry India (CTRI)-CTRI/2022/08/044760 on August 8, 2022.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.